GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » Price-to-Owner-Earnings

Betta Pharmaceuticals Co (SZSE:300558) Price-to-Owner-Earnings : (As of Jun. 04, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Betta Pharmaceuticals Co Price-to-Owner-Earnings?

As of today (2024-06-04), Betta Pharmaceuticals Co's share price is ¥38.77. Betta Pharmaceuticals Co does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Betta Pharmaceuticals Co's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Betta Pharmaceuticals Co was 833.36. The lowest was 195.03. And the median was 376.69.


SZSE:300558's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 26.12
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-04), Betta Pharmaceuticals Co's share price is ¥38.77. Betta Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.93. Therefore, Betta Pharmaceuticals Co's PE Ratio for today is 41.69.

As of today (2024-06-04), Betta Pharmaceuticals Co's share price is ¥38.77. Betta Pharmaceuticals Co's EPS without NRI for the trailing twelve months (TTM) ended in was ¥0.93. Therefore, Betta Pharmaceuticals Co's PE Ratio without NRI for today is 41.60.

During the past 13 years, Betta Pharmaceuticals Co's highest PE Ratio without NRI was 540.15. The lowest was 36.64. And the median was 85.83.


Betta Pharmaceuticals Co Price-to-Owner-Earnings Historical Data

The historical data trend for Betta Pharmaceuticals Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Betta Pharmaceuticals Co Price-to-Owner-Earnings Chart

Betta Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 396.20 - - -

Betta Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Betta Pharmaceuticals Co's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Betta Pharmaceuticals Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Betta Pharmaceuticals Co's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Betta Pharmaceuticals Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Betta Pharmaceuticals Co's Price-to-Owner-Earnings falls into.



Betta Pharmaceuticals Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Betta Pharmaceuticals Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=38.77/-0.78
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Betta Pharmaceuticals Co  (SZSE:300558) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Betta Pharmaceuticals Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Betta Pharmaceuticals Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Betta Pharmaceuticals Co (SZSE:300558) Business Description

Traded in Other Exchanges
N/A
Address
No.355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Zhejiang Province, Hangzhou, CHN
Betta Pharmaceuticals Co Ltd is a hi-tech pharmaceutical enterprise focuses on research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates through China.
Executives
Wang Jia Bing Directors, executives
Ding Lie Ming Directors, executives
Cai Wan Yu Executives

Betta Pharmaceuticals Co (SZSE:300558) Headlines

No Headlines